🇺🇸 FDA
Patent

US 11219695

Methods and compositions for the treatment of Fabry disease

granted A61KA61K38/465A61K48/0058

Quick answer

US patent 11219695 (Methods and compositions for the treatment of Fabry disease) held by Sangamo Therapeutics, Inc. expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/465, A61K48/0058, A61K48/0075, A61P